T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XYZ
Block Inc
XYZ
|
+$2.39B |
| 2 |
Carvana
CVNA
|
+$1.82B |
| 3 |
Microsoft
MSFT
|
+$1.5B |
| 4 |
Walt Disney
DIS
|
+$1.25B |
| 5 |
Spotify
SPOT
|
+$1.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$2.65B |
| 2 |
Intuit
INTU
|
+$2.08B |
| 3 |
Match Group
MTCH
|
+$1.87B |
| 4 |
Salesforce
CRM
|
+$1.76B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.61B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.08% |
| 2 | Healthcare | 16.24% |
| 3 | Consumer Discretionary | 15.33% |
| 4 | Communication Services | 13.82% |
| 5 | Financials | 12.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
LPL Financial
LPLA
$29.4B
| $97.4M | 0.01% |
621,181
+16,746
| +3% | +$2.41M |
|
777
Medpace
MEDP
$16.4B
| $97.1M | 0.01% |
513,229
-189,782
| -27% | -$34.6M |
|
|
HNGR
778
DELISTED
Hanger Inc.
HNGR
| $97.1M | 0.01% |
4,419,513
+26,243
| +0.6% | +$608K |
|
779
Emerson Electric
EMR
$90.7B
| $96.8M | 0.01% |
1,027,953
-296,126
| -22% | -$29.5M |
|
780
ResMed
RMD
$32.7B
| $96.6M | 0.01% |
366,591
+2,042
| +0.6% | +$558K |
|
781
Novavax
NVAX
$1.34B
| $96.6M | 0.01% |
465,919
+76,195
| +20% | +$16.8M |
|
782
Evergy
EVRG
$19.3B
| $96.4M | 0.01% |
1,550,378
-1,636,377
| -51% | -$107M |
|
|
IAA
783
DELISTED
IAA, Inc. Common Stock
IAA
| $96M | 0.01% |
1,759,560
+32,257
| +2% | +$1.79M |
|
|
RDUS
784
DELISTED
Radius Health, Inc.
RDUS
| $95.5M | 0.01% |
7,691,671
-278,505
| -3% | -$4.01M |
|
|
PARA
785
DELISTED
Paramount Global Class B
PARA
| $95.4M | 0.01% |
2,415,775
-349,192
| -13% | -$14.2M |
|
|
CVET
786
DELISTED
Covetrus, Inc. Common Stock
CVET
| $95.3M | 0.01% |
5,255,977
-1,131,339
| -18% | -$25.9M |
|
787
Eaton
ETN
$177B
| $94.7M | 0.01% |
634,031
-9,435
| -1% | -$1.51M |
|
|
BFS
788
Saul Centers
BFS
$860M
| $94.4M | 0.01% |
2,142,386
+9,438
| +0.4% | +$426K |
|
789
BioMarin Pharmaceuticals
BMRN
$13.3B
| $93.9M | 0.01% |
1,214,887
-445,429
| -27% | -$35.1M |
|
790
AMN Healthcare
AMN
$1.3B
| $93.7M | 0.01% |
816,535
-33,562
| -4% | -$3.56M |
|
|
HZNP
791
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $93.6M | 0.01% |
854,191
-55,275
| -6% | -$5.74M |
|
792
Timken Company
TKR
$9.1B
| $93.4M | 0.01% |
1,428,355
-45,657
| -3% | -$3.39M |
|
793
Tidewater
TDW
$4.55B
| $93.4M | 0.01% |
7,743,845
+453,131
| +6% | +$5.15M |
|
794
IQVIA
IQV
$39.4B
| $91.8M | 0.01% |
383,295
-11,792
| -3% | -$2.98M |
|
795
Unifirst Corp
UNF
$5.22B
| $91.7M | 0.01% |
431,440
-40,135
| -9% | -$8.83M |
|
796
Charles River Laboratories
CRL
$13.5B
| $91.5M | 0.01% |
221,784
-65,081
| -23% | -$27M |
|
797
Trane Technologies
TT
$106B
| $90.7M | 0.01% |
525,466
-14,619
| -3% | -$2.81M |
|
798
Dime Commercial Bancshares
DCOM
$1.82B
| $90.7M | 0.01% |
2,776,959
-699,214
| -20% | -$22.7M |
|
799
Takeda Pharmaceutical
TAK
$55.5B
| $90.4M | 0.01% |
5,518,932
+132,629
| +2% | +$2.23M |
|
800
Edison International
EIX
$26.7B
| $90.2M | 0.01% |
1,625,341
-3,620,493
| -69% | -$208M |
|
Similar funds
T. Rowe Price Associates's Q3 2021 Portfolio in Review
As of Q3 2021, T. Rowe Price Associates held 3,048 positions worth $1.06T, down 1.6% from $1.08T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q3 2021 filing shows 131 new, 1,029 increased, 1,524 reduced and 112 closed positions. Its largest new stake was Warby Parker: 17,643,113 shares worth $936M. The largest sale was Visa, an estimated $2.65B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2021 buy was Warby Parker: 17,643,113 shares worth $936M.
- T. Rowe Price Associates added most to Block Inc in Q3 2021, an estimated $2.39B increase.
- T. Rowe Price Associates's biggest Q3 2021 reduction was Visa, cutting an estimated $2.65B.
- T. Rowe Price Associates fully exited Maxim Integrated Products in Q3 2021, selling an estimated $394M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.06T portfolio in Q3 2021.
- T. Rowe Price Associates opened 131 new positions and closed 112 in Q3 2021.
- T. Rowe Price Associates's portfolio value fell 1.6% quarter-over-quarter to $1.06T.
Based on T. Rowe Price Associates's 13F filing for Q3 2021, filed 15 Nov 2021.